At Mundipharma Research, we develop therapies for patients around the world with rare or relapsed/refractory (difficult to treat) cancer, and investigate smart approaches to new cancer treatments, from concept through to clinical development and regulatory approval.
Mundipharma Research has a long heritage in oncology that has enabled us to bring together a team of passionate medical and operational oncology specialists, who work in partnership with a wide network of clinical experts and consultants.
Despite breakthroughs in treatment, there is still unmet patient need.
Blood cancers affect the production and function of blood cells. They include cancers such as multiple myeloma, leukaemias and lymphomas.
Solid tumours may be benign (non-cancerous) or malignant (cancerous). They are formed from a mass of tissue that does not include liquid and are named for the type of cells from which they originate. Solid tumours include sarcomas and carcinomas.
Since 1st January 2020, the Mundipharma Early Development in Oncology development programme is run by Mundipharma Research.
As of 1st January 2020, Mundipharma Early Development in Oncology is now part of Mundipharma R&D, with leadership and resources based at Mundipharma Research Limited. You have been re-directed to the Mundipharma Research website.
Press return to search